Equities Analysts Issue Forecasts for DRUG FY2026 Earnings

Bright Minds Biosciences Inc. (NASDAQ:DRUG) – Equities research analysts at HC Wainwright increased their FY2026 earnings per share (EPS) estimates for Bright Minds Biosciences in a research report issued to clients and investors on Wednesday, August 19th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($3.15) per share for the year, up from their prior forecast of ($5.92). HC Wainwright currently has a “Buy” rating and a $145.00 target price on the stock. The consensus estimate for Bright Minds Biosciences’ current full-year earnings is ($3.85) per share. HC Wainwright also issued estimates for Bright Minds Biosciences’ Q4 2026 earnings at ($1.38) EPS, Q1 2027 earnings at ($1.30) EPS, Q2 2027 earnings at ($1.57) EPS, Q3 2027 earnings at ($1.38) EPS, Q4 2027 earnings at ($1.56) EPS, FY2027 earnings at ($5.83) EPS, FY2028 earnings at ($5.04) EPS, FY2029 earnings at ($2.79) EPS and FY2030 earnings at $2.41 EPS.

A number of other equities research analysts also recently commented on DRUG. Benchmark reissued a “buy” rating on shares of Bright Minds Biosciences in a research report on Thursday. Oppenheimer downgraded shares of Bright Minds Biosciences to a “market perform” rating in a research note on Thursday. Wall Street Zen upgraded Bright Minds Biosciences from a “strong sell” rating to a “sell” rating in a research note on Saturday, July 4th. Zacks Research raised Bright Minds Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. Finally, Piper Sandler reissued an “overweight” rating and set a $220.00 target price (up from $190.00) on shares of Bright Minds Biosciences in a research report on Wednesday, May 20th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Hold rating to the company. According to MarketBeat, Bright Minds Biosciences has a consensus rating of “Buy” and an average price target of $143.83.

Bright Minds Biosciences Price Performance

Shares of Bright Minds Biosciences stock opened at $78.56 on Friday. The stock has a market capitalization of $764.39 million, a price-to-earnings ratio of -37.77 and a beta of -5.27. The business has a 50-day moving average of $72.11 and a 200 day moving average of $77.11. Bright Minds Biosciences has a 12 month low of $38.00 and a 12 month high of $123.75.

Bright Minds Biosciences (NASDAQ:DRUG) last announced its quarterly earnings results on Monday, August 17th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.22) by $1.05.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in DRUG. Royal Bank of Canada lifted its position in Bright Minds Biosciences by 240.0% during the fourth quarter. Royal Bank of Canada now owns 527 shares of the company’s stock worth $40,000 after buying an additional 372 shares during the period. JPMorgan Chase & Co. lifted its position in Bright Minds Biosciences by 624.3% during the second quarter. JPMorgan Chase & Co. now owns 2,173 shares of the company’s stock valued at $57,000 after buying an additional 1,873 shares in the last quarter. Russell Investments Group Ltd. purchased a new stake in Bright Minds Biosciences during the 3rd quarter worth $58,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Bright Minds Biosciences in the second quarter valued at about $66,000. Finally, New York State Common Retirement Fund purchased a new stake in shares of Bright Minds Biosciences during the second quarter valued at approximately $107,000. Institutional investors and hedge funds own 40.52% of the company’s stock.

Bright Minds Biosciences News Summary

Here are the key news stories impacting Bright Minds Biosciences this week:

• Positive Sentiment: HC Wainwright raised earnings estimates across most forecast periods. The firm improved its EPS outlook for FY2026 to $(3.15) from $(5.92), FY2027 to $(5.83) from $(9.07), FY2028 to $(5.04) from $(7.93), and FY2029 to $(2.79) from $(4.04). Quarterly estimates for Q4 2026 through Q4 2027 were also raised, suggesting expectations for narrower losses. HC Wainwright Reaffirms Buy Rating for Bright Minds Biosciences
• Positive Sentiment: The analyst maintained a Buy rating and a $145 price target. The target implies substantial potential upside from the stock’s recent trading level and reinforces confidence in Bright Minds’ development and commercialization prospects. HC Wainwright Reiterates Buy Rating on Bright Minds Biosciences
• Positive Sentiment: The revised estimates point to a possible transition toward profitability. HC Wainwright forecasts positive EPS of $2.41 by FY2030, while the company recently exceeded quarterly EPS expectations, reporting a loss of $(0.17) versus the consensus loss estimate of $(1.22).
• Negative Sentiment: HC Wainwright lowered its FY2030 EPS forecast to $2.41 from $3.09. Although the estimate remains profitable, the reduction represents a longer-term downside revision and highlights continuing uncertainty around the timing and scale of Bright Minds’ earnings potential.

Bright Minds Biosciences Company Profile

Bright Minds Biosciences Inc, trading on the NASDAQ under the symbol DRUG, is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for mental health and neurodegenerative disorders. The company’s research leverages proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds derived from psychedelic-inspired structures. Bright Minds aims to address unmet needs in conditions such as major depressive disorder, post-traumatic stress disorder and Alzheimer’s disease through orally administered treatments.

The company’s lead candidate, BMB-101, is an oral 5-HT2A receptor-modulating compound in clinical development for mood and anxiety disorders.